- Home
- SD vs TNGX Comparison
SD vs TNGX Comparison
Compare SD & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SD
- TNGX
- Stock Information
- Founded
- SD 2006
- TNGX 2014
- Country
- SD United States
- TNGX United States
- Employees
- SD 104
- TNGX N/A
- Industry
- SD Oil & Gas Production
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- SD Energy
- TNGX Health Care
- Exchange
- SD Nasdaq
- TNGX Nasdaq
- Market Cap
- SD 351.0M
- TNGX 317.4M
- IPO Year
- SD 2007
- TNGX N/A
- Fundamental
- Price
- SD $9.62
- TNGX $1.29
- Analyst Decision
- SD
- TNGX Strong Buy
- Analyst Count
- SD 0
- TNGX 7
- Target Price
- SD N/A
- TNGX $12.33
- AVG Volume (30 Days)
- SD 395.1K
- TNGX 756.3K
- Earning Date
- SD 05-06-2025
- TNGX 05-07-2025
- Dividend Yield
- SD 4.62%
- TNGX N/A
- EPS Growth
- SD 3.05
- TNGX N/A
- EPS
- SD 1.69
- TNGX N/A
- Revenue
- SD $125,290,000.00
- TNGX $42,069,000.00
- Revenue This Year
- SD $37.50
- TNGX N/A
- Revenue Next Year
- SD $5.17
- TNGX N/A
- P/E Ratio
- SD $5.69
- TNGX N/A
- Revenue Growth
- SD N/A
- TNGX 15.17
- 52 Week Low
- SD $8.81
- TNGX $1.11
- 52 Week High
- SD $14.85
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- SD 40.02
- TNGX 37.63
- Support Level
- SD $9.14
- TNGX $1.25
- Resistance Level
- SD $9.77
- TNGX $1.44
- Average True Range (ATR)
- SD 0.51
- TNGX 0.15
- MACD
- SD -0.07
- TNGX 0.03
- Stochastic Oscillator
- SD 29.24
- TNGX 45.00
About SD SandRidge Energy Inc.
SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. Its primary areas of operation are the Mid-Continent in Oklahoma and Kansas.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.